Evidence map›Paper›PMID 36082022›Full record

ArticleCancer research communications2022

GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A-mutated tumors.

Valentino Clemente, Asumi Hoshino, Mihir Shetty, Andrew Nelson, Britt K Erickson, Ruth Baker, Nathan Rubin, Mahmoud Khalifa, S John Weroha, Emil Lou and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Valentino ClementeMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Asumi HoshinoMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Mihir ShettyMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Andrew NelsonDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
Britt K EricksonMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Ruth BakerMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Nathan RubinBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Mahmoud KhalifaDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
S John WerohaDepartments of Oncology and Molecular Pharmacology, Mayo Clinic, Rochester, MN, USA.
Emil LouDivision of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Martina BazzaroMasonic Cancer Center and Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USMayo Clinic · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Investigation of the role of UNC-45A in Paclitaxel-mediated microtubule stabilityR01GM130800 · NIGMS · UNIVERSITY OF MINNESOTA · PI BAZZARO, MARTINA · 2019 to 2020
$614k
NCI NIH HHS P30 CA077598NIGMS NIH HHS R01 GM130800
6 · The paper itself

Abstract

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical trials, with promising results. The first clinical trial of CB839 in platinum-resistant ovarian cancer patients is forthcoming.

Indexed as

Adenocarcinoma, Clear CellOvarian NeoplasmsAnimalsDNA-Binding ProteinsFemaleGlutaminaseGlutamineHumansMiceProtective FactorsTranscription FactorsARID1A protein, humanArid1a protein, mouseDNA-Binding ProteinsGLS1 protein, mouseGlutaminaseGlutamineTranscription FactorsARID1ACB839GLS1GlutaminaseGlutaminase inhibitorGlutamineOCCC

Identifiers

PMID36082022
PMCPMC9451103
OpenAlexW4285731193

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.